# Nepafenac Once Daily for Macular Edema - Study 2

> **NCT01872611** · PHASE3 · COMPLETED · sponsor: **Alcon Research** · enrollment: 819 (actual)

## Conditions studied

- Non-Proliferative Diabetic Retinopathy
- Cataract

## Interventions

- **DRUG:** Nepafenac Ophthalmic Suspension, 0.3%
- **OTHER:** Vehicle
- **DRUG:** Prednisolone acetate

## Key facts

- **NCT ID:** NCT01872611
- **Lead sponsor:** Alcon Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 819 (ACTUAL)
- **Last updated:** 2016-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01872611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01872611, "Nepafenac Once Daily for Macular Edema - Study 2". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01872611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*